Charlotte Elwood was diagnosed with a rare ovarian cancer in 1997 and given six months to live. She received multiple ...

The conversion from accelerated approval to traditional approval was supported by data from the phase 3 KEYNOTE-811 trial.

LUND, SE / ACCESS Newswire / March 20, 2025 /Alligator Bioscience (Nasdaq Stockholm:ATORX) today announces that the U.S. Food ...

Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to HLX22 (AC101) ...

The FDA has approved Keytruda plus chemotherapy in HER2+ gastric or GEJ adenocarcinoma with PD-L1–positive expression, based on KEYNOTE-811 data.

The FDA granted orphan drug designation to HLX22 for gastric cancer, advancing global phase 3 trials to improve first-line ...

Shanghai Henlius Biotech, Inc. (2696.HK) announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for HLX22, the company's innovative anti-HER2 monoclonal ...

Moffitt Cancer Center researchers have discovered a promising new vaccine strategy for treating a specific type of breast cancer.

WILMINGTON, DE — NiKang Therapeutics® Inc. has achieved a pivotal step in the development of its first-in-class CDK2 degrader ...

Astellas Pharma’s strong pipeline and revenue growth support a positive outlook. See why ALPMF stock is a "Buy," driven by ...

Abpro Holdings, Inc. (Nasdaq:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-threatening ...

WOBURN, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and ...